title: Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification.
abstract: Hepatitis C virus (HCV) RNA detection and quantification are the key diagnostic tools for the management of hepatitis C. Commercially available HCV RNA assays are calibrated to the HCV genotype 1 (gt1)-based WHO standard. Significant differences between assays have been reported. However, it is unknown which assay matches the WHO standard best, and little is known about the sensitivity and linear quantification of the assays for non-gt1 specimens. Two real-time reverse transcriptase PCR-based assays (RealTime HCV and Cobas Ampliprep/Cobas TaqMan HCV [CAP/CTM]) and one signal amplification-based assay (the Versant HCV RNA, version 3.0, branched DNA [bDNA] assay) were compared for their abilities to quantify HCV RNA in clinical specimens (n = 65) harboring HCV isolates of gt1 to g5. The mean differences in the amounts detected by RealTime HCV in comparison to those detected by the bDNA assay and CAP/CTM were -0.02 and 0.72 log(10) IU/ml HCV RNA, respectively, for gt1; -0.22 and 0.03 log(10) IU/ml HCV RNA, respectively, for gt2; -0.27 and -0.22 log(10) IU/ml HCV RNA, respectively, for gt3; -0.19 and -1.27 log(10) IU/ml HCV RNA, respectively, for gt4; and -0.03 and 0.09 log(10) IU/ml HCV RNA, respectively, for gt5. The lower limits of detection for RealTime HCV and CAP/CTM were 16.8 and 10.3 IU/ml, respectively, for the WHO standard and in the range of 4.7 to 9.0 and 3.4 to 44.4 IU/ml, respectively, for clinical specimens harboring gt1 to gt6. Direct comparison of the two assays with samples of the WHO standard (code 96/798) with high titers yielded slightly smaller amounts by RealTime HCV (-0.2 log(10) at 1,500 IU/ml and -0.3 log(10) at 25,000 IU/ml) and larger amounts by CAP/CTM (0.3 log(10) at 1,500 IU/ml and 0.2 log(10) at 25,000 IU/ml). Finally, all three tests were linear between 4.0 x 10(3) and 1.0 x 10(6) IU/ml (correlation coefficient, >or=0.99). In conclusion, the real-time PCR based assays sensitively detected all genotypes and showed comparable linearities for the quantification of HCV RNA, with the exception of gt1 and gt4. The previously reported differences in the absolute quantification of samples harboring gt1 were confirmed and may be explained by different calibrations to the WHO standard.
authors.affiliation: Zentrum der Inneren Medizin, Medizinische Klinik 1, Klinikum der JW Goethe-Universität, Frankfurt am Main, Germany.
authors.forename: Johannes
authors.initials: J
authors.lastname: Vermehren
authors.forename: Annika
authors.initials: A
authors.lastname: Kau
authors.forename: Barbara C
authors.initials: BC
authors.lastname: Gärtner
authors.forename: Reinhild
authors.initials: R
authors.lastname: Göbel
authors.forename: Stefan
authors.initials: S
authors.lastname: Zeuzem
authors.forename: Christoph
authors.initials: C
authors.lastname: Sarrazin
mesh_terms: D001769:Blood / Q000821:virology*; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D021141:Nucleic Acid Amplification Techniques; D012367:RNA, Viral / Q000032:analysis*; D011933:Reagent Kits, Diagnostic; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D019562:Viral Load / Q000379:methods*
chemical_list: D012367:RNA, Viral; D011933:Reagent Kits, Diagnostic
references.citation: J Clin Microbiol. 2007 Sep;45(9):3077-81
references.pmid: 17581929
references.citation: Hepatology. 2006 May;43(5):954-60
references.pmid: 16628671
references.citation: Hepatology. 2007 Jul;46(1):22-31
references.pmid: 17525931
references.citation: J Clin Microbiol. 2006 May;44(5):1726-32
references.pmid: 16672399
references.citation: Ann Intern Med. 2004 Mar 2;140(5):346-55
references.pmid: 14996676
references.citation: Lancet. 2001 Sep 22;358(9286):958-65
references.pmid: 11583749
references.citation: N Engl J Med. 2002 Sep 26;347(13):975-82
references.pmid: 12324553
references.citation: Am J Clin Pathol. 2007 Aug;128(2):300-4
references.pmid: 17638666
references.citation: J Clin Virol. 2008 Oct;43(2):162-8
references.pmid: 18692434
references.citation: J Clin Virol. 2007 Feb;38(2):96-100
references.pmid: 17185031
references.citation: J Clin Microbiol. 1995 Jan;33(1):254-6
references.pmid: 7699055
references.citation: Lancet. 1986 Feb 8;1(8476):307-10
references.pmid: 2868172
references.citation: Vox Sang. 2002 Jan;82(1):24-31
references.pmid: 11856464
references.citation: Vox Sang. 2005 Apr;88(3):202-4
references.pmid: 15787732
references.citation: J Clin Microbiol. 2002 Sep;40(9):3127-34
references.pmid: 12202542
references.citation: J Virol Methods. 2002 Mar;101(1-2):159-68
references.pmid: 11849694
references.citation: Hepatology. 2006 Aug;44(2):360-7
references.pmid: 16871570
references.citation: J Clin Microbiol. 2007 Nov;45(11):3595-600
references.pmid: 17898157
references.citation: J Clin Microbiol. 2007 Apr;45(4):1140-5
references.pmid: 17251399
references.citation: Hepatology. 2000 Oct;32(4 Pt 1):818-23
references.pmid: 11003628
references.citation: J Clin Microbiol. 2006 Mar;44(3):729-37
references.pmid: 16517847
references.citation: J Hepatol. 2005 Sep;43(3):425-33
references.pmid: 15990196
references.citation: J Clin Microbiol. 2006 Jul;44(7):2507-11
references.pmid: 16825372
references.citation: J Clin Virol. 2007 Oct;40(2):99-104
references.pmid: 17768084
references.citation: J Clin Virol. 2007 Apr;38(4):326-33
references.pmid: 17344093
references.citation: Hepatology. 2003 Sep;38(3):645-52
references.pmid: 12939591
references.citation: J Hepatol. 2005 Apr;42(4):605-6
references.pmid: 15763349